Журнал кардиореспираторных исследований 2026. №3

Тема статьи

Assessment of carbohydrate metabolism in women with ischemic heart disease according to metabolic syndrome status (77-81)

Авторы

Tashkenbayeva E.N., Tuychieva S.K.

Учреждение

Samarkand State Medical University

Аннотация

Cardiovascular diseases remain the leading cause of death among women worldwide, with ischemic heart disease (IHD) representing one of the most prevalent forms of cardiovascular pathology and a major contributor to morbidity and mortality. The prevalence of metabolic syndrome increases significantly after menopause and is associated with insulin resistance, obesity, dyslipidemia, and hypertension. Disturbances in carbohydrate metabolism are considered key mechanisms linking metabolic syndrome and IHD, contributing to an increased risk of adverse cardiovascular outcomes. The study included 168 women aged over 40 years with confirmed ischemic heart disease. Depending on the presence of metabolic syndrome (MS), the patients were divided into two groups: the main group comprised 96 women with IHD and concomitant MS, while the comparison group included 72 women with IHD without MS. Carbohydrate metabolism was evaluated by measuring fasting blood glucose, serum insulin, glycated hemoglobin (HbA1c), and the homeostasis model assessment of insulin resistance (HOMA-IR). Metabolic syndrome in women with ischemic heart disease is associated with significant disturbances in carbohydrate metabolism, including hyperglycemia, hyperinsulinemia, elevated HOMA-IR, and increased HbA1c levels. These findings highlight the important role of insulin resistance in the development of cardiometabolic disorders and emphasize the need for early detection and correction of carbohydrate metabolism abnormalities in women with IHD

Ключевые слова

ischemic heart disease, metabolic syndrome, carbohydrate metabolism, insulin resistance, HOMA-IR

Литературы

1. Adjei N. K. et al. Ethnic differences in metabolic syndrome in high-income countries: a systematic review and meta-analysis //Reviews in Endocrine and Metabolic Disorders. – 2024. – Т. 25. – №. 4. – С. 727-750. 2. Berisha H. et al. Nutrition and lifestyle interventions in managing dyslipidemia and cardiometabolic risk //Nutrients. – 2025. – Т. 17. – №. 5. – С. 776. 3. Brosolo G. et al. Insulin resistance and high blood pressure: mechanistic insight on the role of the kidney //Biomedicines. – 2022. – Т. 10. – №. 10. – С. 2374. 4. Das D. et al. Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies //Frontiers in nutrition. – 2023. – Т. 10. – С. 1221438. 5. Datta S., Koka S., Boini K. M. Understanding the role of adipokines in cardiometabolic dysfunction: a review of current knowledge //Biomolecules. – 2025. – Т. 15. – №. 5. – С. 612. 6. Dobrowolski P. et al. Metabolic syndrome—A new definition and management guidelines //Arterial Hypertension. – 2022. – Т. 26. – №. 3. – С. 99-121. 7. Fahed G. et al. Metabolic syndrome: updates on pathophysiology and management in 2021 //International journal of molecular sciences. – 2022. – Т. 23. – №. 2. – С. 786. 8. Gupta A., Shah K., Gupta V. Interconnected epidemics: obesity, metabolic syndrome, diabetes and cardiovascular diseases—insights from research and prevention strategies //Discover Public Health. – 2025. – Т. 22. – №. 1. – С. 106. 9. Hamooya B. M. et al. Metabolic syndrome: Epidemiology, mechanisms, and current therapeutic approaches //Frontiers in Nutrition. – 2025. – Т. 12. – С. 1661603. 10. Hetherington K. et al. Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk //European journal of pharmacology. – 2024. – Т. 984. – С. 177031 11. Kim H. J., Sohn I. S. Early Menopause and Heart Disease: A Crosstalk With Cardiometabolic Syndrome //CardioMetabolic Syndrome Journal. – 2024. – Т. 4. – №. 2. – С. 49-56. 12. Kodoth V., Scaccia S., Aggarwal B. Adverse changes in body composition during the menopausal transition and relation to cardiovascular risk: a contemporary review //Women's Health Reports. – 2022. – Т. 3. – №. 1. – С. whr. 2021.0119. 13. Lee A. A., Den Hartigh L. J. Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan //Frontiers in Endocrinology. – 2025. – Т. 16. – С. 1682231. 14. Lubogo D. et al. Optimal waist circumference cut-off points for predicting Metabolic Syndrome among females of reproductive age in Wakiso district, central Uganda //PLOS Global Public Health. – 2025. – Т. 5. – №. 4. – С. e0003059. 15. Maas A. H. E. M. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists //European Heart Journal. – 2021. – Т. 42. – №. 10. – С. 967-984 16. Oliveira G. M. M. et al. Brazilian Guideline on Menopausal Cardiovascular Health–2024 //Arquivos Brasileiros de Cardiologia. – 2024. – Т. 121. – С. e20240478 17. Orhan İ., Koçak H. S., Kaplan E. Determination of cardiometabolic risk in pre-and post-menopausal women //BMC Cardiovascular Disorders. – 2025. – Т. 25. – №. 1. – С. 399. 18. Rodriguez de Morales Y. A., Abramson B. L. Cardiovascular and physiological risk factors in women at mid-life and beyond //Canadian journal of physiology and pharmacology. – 2024. – Т. 102. – №. 8. – С. 442-451. 19. Ryczkowska K. et al. Menopause and women’s cardiovascular health: is it really an obvious relationship? //Archives of medicalscience: AMS. – 2022. – Т. 19. – №. 2. – С. 458. 20. van Oortmerssen J. A. E. et al. Lipid metabolism in women: A review //Atherosclerosis. – 2025. – Т. 405. – С. 119213. 21. Varra F. N. et al. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options //Molecular medicine reports. – 2024. – Т. 29. – №. 6. – С. 95. 22. World Heart Federation. World Heart Report 2024: Clearing the Air to Address Pollution's Cardiovascular Health Crisis. Geneva: World Heart Federation; 2024. 124 p. 23. Yi K. A. N. et al. The impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy //Journal of Geriatric Cardiology: JGC. – 2024. – Т. 21. – №. 6. – С. 669. 24. Zhang Z. et al. The Accumulation of Visceral Fat in Postmenopausal Women: The Combined Impact of Prenatal Genetics, Epigenetics, and Fat Depot Heterogeneity—A Descriptive Review //Clinical and Experimental Obstetrics & Gynecology. – 2025. – Т. 52. – №. 2. – С. 26194 25. Баранова Е. И. и др. Гипертоническая болезнь у женщин в пери-и постменопаузе-патофизиологические механизмы и подходы к лечению //Российский кардиологический журнал. – 2023. – Т. 28. – №. 5. – С. 99-107. 26. Беленков Ю. и др. Метаболический синдром: история развития, основные критерии диагностики //Рациональная фармакотерапия в кардиологии. – 2018. – Т. 14. – №. 5. – С. 757-764. 27. Полякова Е. А. и др. Артериальная гипертензия у женщин в пери-и постменопаузальный период: особенности патогенеза, лечения, наблюдения //Российский кардиологический журнал. – 2024. – Т. 29. – №. 1. – С. 49-61. 28. Ташкенбаева Э. Н. и др. Ассоциированные факторы риска кардиоваскулярных событий у женщин в постменопаузальном периоде //Journal of cardiorespiratory research. – 2020. – Т. 1. – №. 3. – С. 33-39